Test Story

By: NewsUSA

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

  • Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.
  • Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643
  • National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins
  • Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.
  • Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.
  • Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.
  • More News

    View More

    Recent Quotes

    View More
    Symbol Price Change (%)
    AMZN  199.34
    -8.20 (-3.95%)
    AAPL  248.80
    -4.09 (-1.62%)
    AMD  201.99
    -1.78 (-0.87%)
    BAC  46.97
    -1.27 (-2.63%)
    GOOG  273.76
    -6.98 (-2.49%)
    META  525.72
    -21.82 (-3.99%)
    MSFT  356.77
    -9.20 (-2.51%)
    NVDA  167.52
    -3.72 (-2.17%)
    ORCL  139.66
    -3.15 (-2.21%)
    TSLA  361.83
    -10.28 (-2.76%)
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.